It’s a Phase III, double-blind placebo-controlled randomized clinical trial of the TLR-3 Agonist Rintatolimod, also known as Ampligen, in 234 subjects.
The fact that it’s a Phase III means that it will be considered as a scientifically validated treatment option.
Positive findings and very exciting news!
To read the PLoS ONE article click here.
To read about journalist Kelvin Lord’s journey on Ampligen you can go to his blog The New Ampligen Diaries.